Background: With the advance of immunotherapy, treatment of non-small-cell lung cancer (NSCLC) has revolutionized by having anti-PD-1 therapy in front-line setting. In this era of cancer immunotherapy, humanized mouse models which recapitulate human immune system, are needed for predicting immunotherapy response in patients. We established a Hu-PBL-NSG mouse model which can be used as a preclinical testing platform for assessing efficacy of different immunotherapeutic agents. Conclusion: Hu-PBL-NSG mouse model which highly resembles human immune system was successfully established. This model could be a strong preclinical model for testing efficacy of immunotherapeutic agents, and also for pursuing novel immunotherapy treatment strategies in advanced NSCLC. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2018.11.035
Authors: Kyoung Ho Pyo, Jae Hwan Kim, Ji-Min Lee, Sung Eun Kim, Jae Seok Cho, Sun Min Lim, Byoung Chul Cho